Kolumn1	Title	Short title	Sponsor	ATMP class	Drug/substance	CTIS, NCT, EudraCT	Year Started	Trial Phase	Trial Status	Disease Area	Indication	Site
1	A phase I study to evaluate safety, feasibility and immunologic response of adoptive T cell transfer with or without dendritic cell vaccination in patients with metastatic melanoma	MAT02	Karolinska Universitetssjukhuset	ex vivo GTMP	TIL +/- DC vacc	2012-000450-63	2013	1	follow-up	Oncology	Melanoma	Karolinska Universitetssjukhuset
2	A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive at the end of consolidation (EOC) therapy	Cassiopeia	Novartis	ex vivo GTMP	Tisagenlekleucel	2017-002116-14	2021	2	follow-up	Pediatric oncology	Pediatric and young adult patients w B ALL	Karolinska Universitetssjukhuset
3	A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM)	TRANSFORM	Celgene	ex vivo GTMP	Lisocabtagene Maraleucel	2018-000929-32, NCT03575351	2018	3	follow-up	Oncology	Large B-cell lymphoma	Karolinska Universitetssjukhuset
4	Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered Tcells, alone or in combination with other agents, in Participants with Advanced Tumors	ZENYTH-ESO	GSK	ex vivo GTMP	TCR T cells	NCT04526509	2019	First-in-human	follow-up	Oncology	Y-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors	Karolinska Universitetssjukhuset
5	A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone	CARTITUDE-4	Janssen	ex vivo GTMP	Ciltacabtagene autoleucel	2019-001413-16, NCT04181827	2020	3	follow-up	Oncology/hematology	Multiple myeloma	Karolinska Universitetssjukhuset
6	A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)	Zuma-4	Kite/Gilead	ex vivo GTMP	KTE-X19	2015-005010-30, NCT02625480	2021	1, 2	recruiting	Pediatric oncology / oncology	Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma	Karolinska Universitetssjukhuset
7	Phase I/IIa, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of CLDN6 CAR-T with or without CLDN6 RNA-LPX in patients with CLDN6-positive relapsed or refractory advanced solid tumors	Cloudin-6 BNT211-01	BioNTech Cell & Gene Therapies	ex vivo GTMP	CAR T	2019-004323-20, NCT04503278	2021	1/2a	recruiting	Oncology	CLDN6 positiva tumörer relaserande eller refraktära	Karolinska Universitetssjukhuset
8	An open, randomised, controlled phase II trial ofCellProtect in combination with isatuximab antibody versus Isatuximab antibody alone as maintenance treatment in patients with Multiple Myeloma undergoing high dose treatment	Cell protect - ISA HC NK	Karolinska Institutet	ex vivo GTMP	CellProtect	2020-000994-26	2021	2	recruiting	Oncology/hematology	Multiple myeloma	Karolinska Universitetssjukhuset
9	A First-In-Human, Phase I/IIa Trial of the novel T cell Immunotherapy pTTL in Patients with Advanced Colorectal Cancer	NEOGAP-CRC-01	NeoGap	ex vivo GTMP	NeoGap	2022-000394-96	2022	1/2a	recruiting	Oncology	Advanced colorectal cancer	Karolinska Universitetssjukhuset

10	An adaptive open-label multicenter, phase 1/2 trial to determine the recommended phase 2 dose of CCTx-001 and assess safety, tolerability and clinical activity in patients with relasped/refractory acute myeloid leukaemia	RESOLVE	Advesya SAS	ex vivo GTMP	CCTx-001	NCT06281847	2024	1/2a	planning	Oncology/hematology	Acute myeloid leukaemia	Karolinska Universitetssjukhuset
11	En klinisk studie på stamcellsbehandling av medfödd benskörhet som ges före eller strax efter födseln (BOOSTB4)	BOOSTB4	BOOSTPhama	sCTMP	MSC	2015-003699-60	2019	2	follow-up	Pediatrics	Osteogenesis imperfecta	Karolinska Universitetssjukhuset
12	A phase I/II study in patients with severe vocal fold scarring treated with autologus mesenchymal stromal cell product MSC-KI-PL-204	MSC-KI-PL-204	Karolinska Institutet	sCTMP	MSC-KI	NCT04290182	2021	1	follow-up	ENT	Vocal fold scarring	Karolinska Universitetssjukhuset
13	A Randomised, Open label, Multicentre, Phase 3 Trial of First line Treatment with Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Adult and Adolescent Subjects with Steroid refractory Acute Graft versus host Disease After Allogeneic Haematopoietic Stem Cell Transplantation (IDUNN Trial)	IDUNN	Syneos Health	sCTMP	MC0518	2019-001462-15	2022	3	recruiting	Immune system disorders	Steroid refractory aGvHD	Karolinska Universitetssjukhuset
14	A phase IA/IB open-label, dose-escalation study of the safety and pharmakokinetics of RO7198457 as a single agent and in combination with atezolizumab in patients with locally advanced or metastatic tumours	AteVacc	Genentech, Inc.	in vivo GTMP	autogene cevumeran (RO7198457)	2017-001475-23, NCT03289962	2021	1	follow-up	Oncology	Locally Advanced or Metastatic Tumors	Karolinska Universitetssjukhuset
15	Oncolytic Adenovirus for Cancer	LOKON002	LOKON Pharma	in vivo GTMP	Delolimogene mupadenorepvec (LOAd703)	2017-002565-22, NCT03225989	2021	1, 2	follow-up	Oncology - endocrinology	Pancreatic and ovary cancer	Karolinska Universitetssjukhuset
16	An Open-label First-in-human Single Ascending Dose Study to Explore Safety, Tolerability and Efficacy of Subretinal Administration of CPK850 Gene Therapy in Patients With Retinitis Pigmentosa Due to Mutations in the Retinaldehyde Binding Protein 1 (RLBP1) Gene	CPK850	Novartis	in vivo GTMP	CPK850	2016-002696-10	2018	1, 2	follow-up	Ophtamology	Bothniadystrofi, retinitis pigmentosa	St Eriks Ögonsjukhus
17	Oncolytic Virus BI 1467-0001, An open-label, Phase I dose escalation and expansion trial to investigate safety and efficacy of BI 1821736 in patients with advanced solid tumors	OnkoVir	Boeringer Ingelheim	in vivo GTMP	BI 1467-0001	2022-502125-17-00, NCT05839600	2023	First-in-human	recruiting	Oncology	Advanced solids tumours	Karolinska Universitetssjukhuset
18	A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of SRP-9001 in Non-Ambulatory and Ambulatory Subjects With Duchenne Muscular Dystrophy (ENVISION)	ENVISION	Sarepta Therapeutics	in vivo GTMP	Delandistrogene moxeparvovec (SRP-9001)	2020-002373-13, NCT05881408	2023	3	recruiting	Pediatrics	Duchennes muskeldystrofi	Karolinska Universitetssjukhuset
19	A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)	PARASOL	J & J	in vivo GTMP	JNJ-81201887	NCT05811351	2024	2b	recruiting	Ophtamology	Geographic atrophy, secondary to age-related macular degeneration	St Eriks Ögonsjukhus
20	MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)	MAGNITUDE	Intellia Therapeutics	in vivo GTMP	NTLA-2001	2023-507220-23-00, NCT06128629	2024	3	planning	Cardiology	Transthyretin Amyloidosis w. Cardiomyopathy, ATTR-CM	Karolinska Universitetssjukhuset